drugset / Trial / NCT04613492
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study D7880C00001 is a first-in-human (FIH), Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of MEDI9253 in combination with durvalumab in adult participants with select advanced/metastatic solid tumors.
Timeline
- Start
- 2020-12-02
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
Outcome
Outcome not reported
Stopped: “The study was terminated early due to lack of efficacy and absence of biomarker evidence of MEDI9253's impact on the tumors.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | MEDI9253 | Unknown | — | Intravenous |